SAB Biotherapeutics, Inc. $SABS Holdings Lifted by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP raised its position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 47.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 736,077 shares of the company’s stock after acquiring an additional 236,077 shares during the quarter. Seven Fleet Capital Management LP’s holdings in SAB Biotherapeutics were worth $2,871,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. PNC Financial Services Group Inc. bought a new position in SAB Biotherapeutics in the 1st quarter worth approximately $29,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the 3rd quarter worth $32,000. State of Wyoming acquired a new position in SAB Biotherapeutics during the 4th quarter worth $34,000. Finally, Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth $40,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $3.72 on Friday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a market cap of $338.48 million, a price-to-earnings ratio of -2.86 and a beta of 0.53. The business has a fifty day simple moving average of $3.74 and a 200-day simple moving average of $3.77. SAB Biotherapeutics, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). On average, equities analysts forecast that SAB Biotherapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Barclays started coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price target on the stock. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Weiss Ratings raised shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Citigroup initiated coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target on the stock. Finally, Leerink Partners upped their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.